Furthermore, in the most frequent mutated genes in relapsed/refractory cHL patients (CREBBP (60%), NOTCH2 (50%), PTPRD (50%), SF3B1 (50%), and ARID1A, EP300, NOTCH1, PLCG2 (30% each one)), no statistically significant differences were observed in our cohort. This evidence concerns the gene PLCG2 and classic Hodgkin lymphoma.